Last Updated on October 6, 2024 by The Health Master
PLI scheme
The Indian government is leaving no stone unturned to bolster the country’s pharmaceutical industry.
A key initiative in this direction is the Production Linked Incentive (PLI) Scheme for Pharmaceuticals.
With a massive budget of Rs 15,000 crore and a six-year timeline ending in FY 2027-28, the scheme aims to incentivize domestic manufacturing of critical drugs.
Focus on High-Value Drug Categories
To make a significant impact, the PLI scheme has identified three key product categories for support:
- Bio-pharmaceuticals: These complex and high-value drugs are engineered using living organisms.
- Complex generics: Generic versions of patented drugs that require advanced manufacturing processes.
- Gene therapy drugs, complex excipients, and orphan drugs: These are specialized medications for rare diseases and specific medical conditions.
PLI Scheme Supports Orphan Drug Production
A particularly noteworthy aspect of the PLI scheme is its focus on orphan drugs.
These life-saving medications cater to patients with rare diseases, often neglected by the pharmaceutical industry due to limited market size.
The government has identified eight crucial orphan drugs for manufacturing under the PLI scheme:
| Sr. No. | Product Name | Usage |
|---|---|---|
| 1 | Nitisinone | Treatment of Hereditary Tyrosinemia Type 1 |
| 2 | Nusinersen | Treatment of Spinal Muscular Atrophy |
| 3 | Rufinamide | Treatment of Lennox-Gastaut syndrome |
| 4 | Sodium Phenyl Butyrate | Treatment of Urea Cycle Disorders |
| 5 | Tiopronin | Prevention of Cystine Nephrolithiasis |
| 6 | Trientine Hydrochloride | Treatment of Wilson’s disease |
| 7 | Eliglustat | Treatment of Gaucher’s disease |
| 8 | Cannabidiol | Treatment of Dravet-Lennox Gastaut syndrome |
By promoting the domestic production of these orphan drugs, India is taking a major step towards ensuring affordable and accessible treatment options for patients suffering from rare diseases.
The announcement was made by Union Minister of State for Chemicals and Fertilizers, Anupriya Patel, in the Lok Sabha, underlining the government’s commitment to improving healthcare access for all citizens.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Govt targets Rs. 90,000 crore Pharma Industry under PLI scheme
Govt approved 746 applications till November under PLI Schemes
The 5th Round of PLI Scheme Applications in Medical Devices
3 PLI Schemes: Transforming India’s Pharma Industry
PLI Scheme: Boosting Pharmaceutical and Medical Device Manufacturing
USFDA issues Form 483 with 3 observations to Gland Pharma
Imports of Bulk Drugs from China grew 8.8 %
CDSCO approval granted for Beyfortus in India
Human Error: The Silent Killer of the Indian Pharma Industry
Drug Recall in India: A Growing Concern
USFDA India appoints Greg Smith as New Director
RBI: Indian Pharma Industry faces Quality Control Overhaul
How the NPPA Regulates Medicine Prices in India
India seeks new Head for Drug Regulators CDSCO
Jyoti Sardesai a veteran Administrator retires after Four Decades of Service
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
